RxDoctor Payments DataLook up a doctor →

Christie Morrison

Acute Care · San Antonio, TXNPI 1760875165

Payments from drug & device makers

$225,148in general payments, 2019–2025

Across 578 payments — averaging $389.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$199K
  • Pfizer$12K
  • Lilly USA, LLC$6K
  • Johnson & Johnson$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • plus $3K from 20 others

What the payments were for

  • Consulting fees$6,2113%
  • Speaking & faculty fees$136,91361%
  • Travel & lodging$67,14930%
  • Food & beverage$14,8477%
  • Education$290%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$225,148 in reported general payments places this provider in the 95th percentile of 2,323 acute care providers in Texas.

See all acute care providers in Texas

Medicare billing

Part B allowed, 2024
$34,260
Medicare patients
56
Services billed
1,627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi On-BodyRisankizumab-Rzaa17$350,488
RinvoqUpadacitinib16$135,866
LinzessLinaclotide31$27,833
GimotiMetoclopramide Hcl11$23,341
TrulancePlecanatide13$7,143
Lubiprostone18$1,504
Omeprazole76$1,411
Rabeprazole Sodium22$834
Pantoprazole Sodium105$719
Lactulose15$631
Colestipol Hcl16$474
Esomeprazole Magnesium15$378
Ondansetron OdtOndansetron11$320
Famotidine11$205
Metoclopramide Hcl15$71

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Linzess$199,144$163,69947 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$104$7,14313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,323 acute care providers in Texas.

Other acute care in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →